Azacitidine combined with the selective FLT3 kinase inhibitor crenolanib disrupts stromal protection and inhibits expansion of residual leukemia-initiating cells in FLT3-ITD AML with concurrent epigenetic mutations.
about
Azacitidine combined with the selective FLT3 kinase inhibitor crenolanib disrupts stromal protection and inhibits expansion of residual leukemia-initiating cells in FLT3-ITD AML with concurrent epigenetic mutations.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
Azacitidine combined with the ...... ncurrent epigenetic mutations.
@en
Azacitidine combined with the ...... ncurrent epigenetic mutations.
@nl
type
label
Azacitidine combined with the ...... ncurrent epigenetic mutations.
@en
Azacitidine combined with the ...... ncurrent epigenetic mutations.
@nl
prefLabel
Azacitidine combined with the ...... ncurrent epigenetic mutations.
@en
Azacitidine combined with the ...... ncurrent epigenetic mutations.
@nl
P2093
P2860
P50
P356
P1433
P1476
Azacitidine combined with the ...... ncurrent epigenetic mutations.
@en
P2093
Anne-Kathrin Garz
Christian Peschel
Christian Thiede
Katharina S Götze
Konstanze Döhner
Marie-Theresa Weickert
Martha Smets
Martina Rudelius
Saskia Wolf
Sebastian Bultmann
P2860
P304
108738-108759
P356
10.18632/ONCOTARGET.21877
P407
P577
2017-10-16T00:00:00Z